A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679
NCT00511563 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2015-03-02
Summary
To better understand the way that GW876008 and GSK561679 work on hormone responses in patients with Irritable Bowel Syndrome.
Conditions
- Irritable Bowel Syndrome
Interventions
- DRUG
-
GW876008 and GSK561679
GW876008 and GSK561679
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
GSK Clinical Trials · GlaxoSmithKline
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-08-31
- Primary Completion
- 2012-11-30
More Related Trials
-
A Study of BMS-562086 in Patients With Irritable Bowel Syndrome
NCT00399438 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects
NCT02798991 ·Status: COMPLETED ·Phase: PHASE1
-
Diarrhea Predominant Irritable Bowel Syndrome in Females
NCT00461526 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)
NCT00268879 ·Status: COMPLETED ·Phase: PHASE3
-
Study Of Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy
NCT00067561 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)
NCT00607971 ·Status: TERMINATED ·Phase: PHASE3
-
Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
NCT05795049 ·Status: ACTIVE_NOT_RECRUITING
-
A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
NCT01340053 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Tegaserod on Patterns of Flow in the Small Bowel of Patients With Irritable Bowel Syndrome (IBS)
NCT00171431 ·Status: TERMINATED ·Phase: PHASE3
-
Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)
NCT01149200 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of an Encapsulated Probiotic Bifidobacterium Infantis 35624 in Irritable Bowel Syndrome
NCT00135031 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Tegaserod in Relieving the Symptoms of Female Patients With Irritable Bowel Syndrome (IBS), Excluding Those With Predominant Diarrhea IBS
NCT00142987 ·Status: COMPLETED ·Phase: PHASE4
-
Donor Selection for Faecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT06171126 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Postinfectious Irritable Bowel Syndrome and Gelsectan
NCT05045768 ·Status: COMPLETED ·Phase: PHASE4
-
Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS)
NCT00610909 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Evaluation of Fecal Microbiota Transplantation in Irritable Bowel Syndrome
NCT05740319 ·Status: RECRUITING ·Phase: NA
-
Study to Assess the Efficacy and Safety of SKI3246 in Subjects With Non-Constipation Irritable Bowel Syndrome
NCT02079675 ·Status: COMPLETED ·Phase: PHASE2
-
Postprandial Lipids in IBS and Nutritional Treatment
NCT05016596 ·Status: COMPLETED ·Phase: NA
-
A Phase 1, First Time in Human (FTIH) Study to Evaluate GSK3352589, a REarranged During Transfection (RET) Growth Factor Receptor Tyrosine Kinase Inhibitor, in Healthy Volunteers
NCT03154086 ·Status: COMPLETED ·Phase: PHASE1
-
Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome
NCT02249169 ·Status: COMPLETED
-
A Study of 3 Doses of Dextofisopam in Females With Irritable Bowel Syndrome
NCT00486876 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Efficacy of Different Mixes of HMO-2FL + Humiome® Post LB on IBS Gastrointestinal Symptoms
NCT06889779 ·Status: RECRUITING ·Phase: NA
-
Safety and Efficacy Study of GR68755 (Alosetron Hydrochloride) to Treat Severe Diarrhea-Predominant Irritable Bowel Syndrome (IBS)
NCT01855711 ·Status: COMPLETED ·Phase: PHASE2
-
Genetic Carbohydrate Maldigestion As Model to Study Food Hypersensitivity Mechanism (WORK PACKAGE 2)
NCT06770907 ·Status: NOT_YET_RECRUITING
-
IQP-CL-101 in IBS Management
NCT01774825 ·Status: COMPLETED ·Phase: PHASE3